American Diabetes Association Meeting In Brief
This article was originally published in The Gray Sheet
Executive Summary
Diabetes diagnosis: A1C assays, which provide results reflecting average glucose levels over a 2-3 month period, should be the new standard test for making an initial diagnosis of diabetes, an international committee of experts recommended June 5 at the American Diabetes Association annual scientific sessions in New Orleans. A1C is a standard tool for monitoring and managing treatment for diabetes, but diagnosis is typically achieved with a fasting plasma glucose test, or, in some cases, an oral glucose tolerance test. The committee, assembled by ADA, the International Diabetes Federation and the European Association for the Study of Diabetes, noted that A1C values vary less than the other tests and that A1C assays have technical and ease-of-use benefits. An A1C value of 6.5% or greater should generally be used for diagnosis, though it cannot be viewed as an absolute dividing line, the committee said. The three organizations have yet to officially endorse the recommendation. Bio-Rad, MEC Dynamics, Bayer and Roche are among dozens of A1C test kit manufacturers
You may also be interested in...
Stent Makers, Interventionists Downplay Impact Of BARI 2D Data
There is little debate that BARI 2D trial data unveiled last week affirmed that percutaneous coronary intervention does not extend the lives of patients with type 2 diabetes and stable ischemic heart disease, but stent manufacturers and interventionalists are scratching their heads as to why anybody would be surprised
Continuous Glucose Monitors: Best Data To Date, But Youths Pose Challenge
Continuous glucose monitor manufacturers expect research reported out of Rome last week will boost the still-nascent market for the products and help make the case for better reimbursement
Tethys Builds A Case For Pre-Diabetes Algorithm-Based Screening
Diagnostics start-up Tethys Bioscience is laying the groundwork for its first product - a lab test it says will improve screening of the more than 50 million people at near-term risk for developing type-2 diabetes and help identify the best candidates for early-stage intervention